Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver

Abstract

Please cite this article as: Elias D., Goéré D., Leroux G., Dromain C., Leboulleux S., de Baere T., Ducreux M., Baudin E. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver., European Journal of Surgical Oncology (2009Oncology ( ), doi: 10.1016Oncology ( /j.ejso.2009 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Accepted ManuscriptTitle: Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver.

Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: A propensity score matching analysis

“…Based on this concept, even more PSHs for CRLMs were performed in recent years. [24][25][26] This change of 9 who demonstrated that, in case of single CRLM of 3 cm, the parenchymal-sparing technique improved survival in case of liver recurrence, allowing for salvage re-hepatectomy as compared to a NON-PSH approach. To our knowledge, there was no report in the literature establishing a comparison between NON-PSH and PSH for multiple bilobar resections for more than 3 lesions which analyzed shortterm and long-term results.…”

Radiofrequency Ablation for Neuroendocrine Liver Metastases: A Systematic Review

“…Surgical options include resection or rarely transplantation, but the majority of patients do not have resectable or "transplantable" disease at presentation, and surgery carries a high recurrence rate (13)(14)(15)(16). Somatostatin analogues are the most effective pharmacologic therapy for symptom control, and traditional chemotherapy has limited efficacy (17,18).…”

Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study

“…However, liver surgery is frequently impossible due to the extent of the disease. Various surgical approaches have been proposed to these patients, such as a two-step surgical procedure or a combination of surgery and radiofrequency ablation [5,6,7,8]. Even with the development of these techniques, the resection of more than 10 or 20 bilateral lesions is usually considered as unfeasible.…”